Alterity Therapeutics Ltd (NASDAQ:ATHE)
| Market Cap | 53.20M-28.1% |
| Revenue (ttm) | 0-31.5% |
| Net Income | -23.42M-8.0% |
| EPS | -1.32+58.3% |
| Shares Out | 16.94M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 24,505 |
| Open | 3.15 |
| Previous Close | 3.32 |
| Day's Range | 3.06 - 3.23 |
| 52-Week Range | 2.66 - 5.89 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 8.00(+154.78%) |
| Earnings Date | Mar 4, 2027 |
ALTERITY THERAPEUTICS LTD has a live Insider Score.
Scored on 1 qualifying trade from 1 insider in the last 90 days.
About ATHE
Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent experimental therapy, ATH434, has completed Phase I clinical trials targeting Parkinson's disease. The company is also advancing PBT2, a compound that has successfully undergone Phase IIa clinical testing for Alzheimer's disease. Established in 1997, the entity was formerly known as Prana Biotechnology Limited before rebranding to Alterity Therapeutics Limited in April 2019, and its main operations are based in Melbourne, Australia.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$ATHE stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in ATHE holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ATHE's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ATHE Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New ATHE patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ATHE from public contracts
Source: USAspending.gov
ATHE Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from ATHE’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score